| 15.13 Delayed Data As of Jun 18 |  +0.40 / +2.72%Today’s Change | 14.61 Today|||52-Week Range 32.32 | -13.89% Year-to-Date |
| Bayer to Invest 5 Billion Euros in Weedkiller Research Jun 17 / Zacks.comZAK - Paid Partner Content | CRISPR Therapeutics Up on Collaboration Expansion by Vertex Jun 10 / Zacks.comZAK - Paid Partner Content |
| Will Bayer's Investment in its Reputation Boost BAYRY Stock? Jun 17 / Zacks.comZAK - Paid Partner Content | Blueprint Medicines to File NDA for Avapritinib With FDA Jun 05 / Zacks.comZAK - Paid Partner Content |
| Previous close | 14.73 |
| Today’s open | 15.00 |
| Day’s range | 14.98 - 15.18 |
| Volume | 592,747 |
| Average volume (3 months) | 908,947 |
| Market cap | $55.3B |
| Earnings growth (last year) | -77.23% |
| Earnings growth (this year) | +14.21% |
| Earnings growth (next 5 years) | +10.51% |
| Revenue growth (last year) | +18.25% |
| P/E ratio | 3.5 |
| Price/Sales | 1.39 |
| Price/Book | 1.05 |
| No competitors data available. |
| Next reporting date | July 30, 2019 |
| EPS forecast (this quarter) | $0.55 |
| Annual revenue (last year) | $46.7B |
| Annual profit (last year) | $2.0B |
| Net profit margin | 4.28% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman- Management Board Werner Baumann |
Chief Financial Officer Wolfgang U. Nickl |
Corporate headquarters Leverkusen, Nordrhein-westfalen |
